Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia.
Kaplan, Steven A.
Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. - 1st ed. - 1 online resource (227 pages)
Intro -- Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia -- Copyright -- Contents -- Contributors -- Chapter 1 Etiology and Pathogenesis -- Introduction -- What is BPH/LUTS? The biology -- Regulation of the normal prostate -- Androgen regulation of the prostate -- Estrogens, progesterone, prostatic regulation, and BPH -- Growth factors and chemokines in BPH/LUTS -- Inflammatory changes associated with BPH -- Prostate-associated Gene 4 as a stress modulator within the prostate -- The need for biomarkers of BPH -- Conclusions -- Bibliography -- Chapter 2 Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: Epidemiology, Correlates, and Risk Factors -- Introduction -- Descriptive epidemiology, risk factors, and correlates -- Metabolic syndrome, obesity, and LUTS -- BPH/LUTS and sexual function in men -- Measurement and classification of LUTS symptoms in epidemiological research: new concepts and methods -- Summary and conclusion -- Bibliography -- Chapter 3 Clinical Assessment and Diagnosis of Lower Urinary Tract Dysfunction: United States -- Introduction -- Initial evaluation of men presenting with LUTS -- Medical history -- Characterization of LUTS and quality of life -- Physical examination -- Initial diagnostic tests -- Differential diagnosis after the initial evaluation -- Evaluation of the persistent or complicated LUTS in the male patient with LUTD -- Diagnostic tests for patients with complicated LUTD -- Additional selected diagnostic tests for complex BPH patients -- Bibliography -- Chapter 4 Clinical Assessment and Diagnosis of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Europe -- Aim of the assessment -- Investigational tests -- Medical history -- Symptom score -- Physical examination and digital rectal examination -- Frequency-volume charts and bladder diaries -- Urinalysis (dipstick). Serum creatinine -- PSA -- Postvoid residual urine -- Imaging of urinary tract -- Endoscopy -- Uroflowmetry -- Pressure-flow studies -- What happens in real life in Europe? -- Bibliography -- Chapter 5 Clinical Assessment and Diagnosis of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Primary Care -- Why should primary care be concerned? -- Definitions -- What are LUTS? -- Normal function of the prostate -- Abnormal function of the prostate -- Normal function of the bladder -- Abnormal function of the bladder -- History, physical, and laboratory evaluation -- Other modalities in assessment -- Reasons for referral -- Assessing bother -- Summary -- Chapter 6 Watchful Waiting -- Introduction -- Symptom progression -- Acute urinary retention -- Prostate size and growth -- Bladder function changes in men over time -- Renal disease and benign prostatic hyperplasia -- Associations in common between chronic kidney disease and benign prostatic hyperplasia -- Inflammation -- Diabetes -- Hypertension -- Metabolic syndrome -- Autonomic nervous system -- Monitoring renal function in men with benign prostatic hyperplasia -- End-stage renal disease -- Conclusion -- Bibliography -- Chapter 7 α-Adrenergic Antagonists for Lower Urinary Symptoms Secondary to Benign Prostatic Hyperplasia -- Introduction -- α-Adrenergic receptors in the prostate -- Nonselective α-blockers -- Selective α-blockers -- Doxazosin -- Terazosin -- Alfuzosin -- Tamsulosin -- Sildosin -- Naftopidil -- α-Adrenergic antagonists and sexual dysfunction -- α1-blockers and intraoperative floppy iris syndrome -- Combination therapy -- Adverse effects of combination therapy for benign prostatic hyperplasia -- Summary -- Chapter 8 5α-Reductase Inhibitors -- Introduction and history of 5α-reductase inhibitors. Hypothetical rationale, preclinical, and early clinical (phase I-II) evidence for the use of 5α-reductase inhibitors in benign prostatic hyperplasia -- Clinical evidence (phase III or higher) for the use of 5α-reductase inhibitors in benign prostatic hyperplasia -- Finasteride -- Dutasteride -- Finasteride versus dutasteride -- Side effects of 5α-reductase inhibitor treatment -- 5α-Reductase inhibitors and prostate cancer -- Bibliography -- Chapter 9 Antimuscarinics -- Introduction -- Mechanism of action -- Clinical studies -- Evidence in men with storage lower urinary tract symptoms -- Evidence in men with confirmed bladder outlet obstruction -- Comparison between agents -- Antimuscarinic safety in men with lower urinary tract symptoms/benign prostatic hyperplasia -- Other important treatment issues -- Practical aspects of antimuscarinic use -- Conclusion -- Conflict of interest -- Chapter 10 The Use of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia -- Introduction -- Epidemiology -- Lower urinary tract symptoms treatment -- Pathophysiology of lower urinary tract symptoms and the phosphodiesterase-5 signal pathway -- Nitric oxide synthase/cyclic guanosine monophosphate pathway -- Ras homolog gene family, member A/Ras homolog-kinase signaling -- Pelvic atherosclerosis and chronic hypoxia -- Autonomic hyperactivity -- Mechanism of action of phosphodiesterase-5 inhibitors in benign prostatic hyperplasia/lower urinary tract symptoms -- Bladder -- Prostate -- Vasculature -- Spinal cord -- Summary of randomized controlled trials of phosphodiesterase-5 inhibitors versus placebo -- Summary of randomized controlled trials of phosphodiesterase-5 inhibitors and urodynamics -- Safety. Evidence-based outcomes of alpha blocker/phosphodiesterase-5 inhibitor combination on lower urinary tract symptoms -- Indications and contraindications -- Limitations -- Chapter 11 Combination Medical Therapy for Male Lower Urinary Tract Symptoms -- Combination medical therapy: alpha receptor blocker + 5α-reductase inhibitor -- Introduction and mechanisms of action -- Small studies of short duration -- Placebo-controlled and direct comparator studies -- Adverse events of α1-blocker/5α-reductase inhibitor combination therapy (Table 11.3) -- Alpha adrenergic receptor blocker + antimuscarinics -- Subjective outcomes of α1-blocker/antimuscarinic combination therapy -- Objective outcomes of α1-blocker/antimuscarinic combination therapy -- Adverse events of α1-blocker/antimuscarinic combination therapy -- Alpha adrenergic receptor blocker + phosphodiesterase type 5 inhibitor -- Clinical studies -- Meta-analysis -- Bibliography -- Chapter 12 Complementary Therapy -- Phytotherapy -- Common compounds in phytochemicals -- β-Sitosterol -- Isoflavones -- Selected phytotherapeutic agents -- Saw palmetto (Serona repens) -- Pygeum (Pygeum africanum) -- Stinging nettle (Urtica dioica et urens) -- South African star grass (Hypoxis rooperi) -- Rye pollen (Secale cerale) -- Pumpkin seeds (Curcubita pepo L.) -- Flaxseed lignans -- Nutrients -- Zinc -- Amino acids -- Fatty acids -- Exercise -- Chapter 13 Open Simple Prostatectomy -- Introduction -- Open simple prostatectomy -- Surgical techniques -- Suprapubic transvesical prostatectomy (Freyer) -- Retropubic transcapsular prostatectomy (Millin) -- Simple perineal prostatectomy -- Perioperative antibiotic prophylaxis -- Postoperative management -- Functional outcomes -- Morbidity and mortality -- Minimally invasive alternatives of simple prostatectomy -- Laparoscopic simple prostatectomy. Robot-assisted simple prostatectomy -- Single-port transvesical enucleation of the prostate -- Bibliography -- Chapter 14 Minimally Invasive Therapies -- Overview -- Transurethral needle ablation of the prostate -- Transurethral microwave thermotherapy -- Transurethral ethanol ablation of the prostate -- Botulinum toxin A -- Bibliography -- Chapter 15 Holmium Laser Prostatectomy -- Introduction -- Laser physics -- History -- Holmium laser enucleation of the prostate technique -- Equipment -- Procedure -- Bladder neck incision -- Median lobe enucleation -- Lateral lobe enucleation -- Haemostasis -- Morcellation -- Modifications -- Patient selection -- Outcomes -- Learning curve -- Conclusion -- Bibliography -- Chapter 16 Benign Prostatic Hyperplasia: GreenLight Laser Therapy -- 532 nm wavelength laser -- 60 W data -- 80 W data -- 120 W -- 180 W 532 nm laser -- Complications -- Conclusion -- Bibliography -- Chapter 17 Principles of Electrocautery-Based Techniques -- Overview -- Monopolar transurethral resection of the prostate -- Early experience with monopolar electrovaporization technology -- Bipolar transurethral resection of the prostate -- Bibliography -- Index.
9781118437971
Lower Urinary Tract Symptoms.
Electronic books.
RC877 -- .M35 2014eb
616.6/5
Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. - 1st ed. - 1 online resource (227 pages)
Intro -- Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia -- Copyright -- Contents -- Contributors -- Chapter 1 Etiology and Pathogenesis -- Introduction -- What is BPH/LUTS? The biology -- Regulation of the normal prostate -- Androgen regulation of the prostate -- Estrogens, progesterone, prostatic regulation, and BPH -- Growth factors and chemokines in BPH/LUTS -- Inflammatory changes associated with BPH -- Prostate-associated Gene 4 as a stress modulator within the prostate -- The need for biomarkers of BPH -- Conclusions -- Bibliography -- Chapter 2 Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: Epidemiology, Correlates, and Risk Factors -- Introduction -- Descriptive epidemiology, risk factors, and correlates -- Metabolic syndrome, obesity, and LUTS -- BPH/LUTS and sexual function in men -- Measurement and classification of LUTS symptoms in epidemiological research: new concepts and methods -- Summary and conclusion -- Bibliography -- Chapter 3 Clinical Assessment and Diagnosis of Lower Urinary Tract Dysfunction: United States -- Introduction -- Initial evaluation of men presenting with LUTS -- Medical history -- Characterization of LUTS and quality of life -- Physical examination -- Initial diagnostic tests -- Differential diagnosis after the initial evaluation -- Evaluation of the persistent or complicated LUTS in the male patient with LUTD -- Diagnostic tests for patients with complicated LUTD -- Additional selected diagnostic tests for complex BPH patients -- Bibliography -- Chapter 4 Clinical Assessment and Diagnosis of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Europe -- Aim of the assessment -- Investigational tests -- Medical history -- Symptom score -- Physical examination and digital rectal examination -- Frequency-volume charts and bladder diaries -- Urinalysis (dipstick). Serum creatinine -- PSA -- Postvoid residual urine -- Imaging of urinary tract -- Endoscopy -- Uroflowmetry -- Pressure-flow studies -- What happens in real life in Europe? -- Bibliography -- Chapter 5 Clinical Assessment and Diagnosis of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Primary Care -- Why should primary care be concerned? -- Definitions -- What are LUTS? -- Normal function of the prostate -- Abnormal function of the prostate -- Normal function of the bladder -- Abnormal function of the bladder -- History, physical, and laboratory evaluation -- Other modalities in assessment -- Reasons for referral -- Assessing bother -- Summary -- Chapter 6 Watchful Waiting -- Introduction -- Symptom progression -- Acute urinary retention -- Prostate size and growth -- Bladder function changes in men over time -- Renal disease and benign prostatic hyperplasia -- Associations in common between chronic kidney disease and benign prostatic hyperplasia -- Inflammation -- Diabetes -- Hypertension -- Metabolic syndrome -- Autonomic nervous system -- Monitoring renal function in men with benign prostatic hyperplasia -- End-stage renal disease -- Conclusion -- Bibliography -- Chapter 7 α-Adrenergic Antagonists for Lower Urinary Symptoms Secondary to Benign Prostatic Hyperplasia -- Introduction -- α-Adrenergic receptors in the prostate -- Nonselective α-blockers -- Selective α-blockers -- Doxazosin -- Terazosin -- Alfuzosin -- Tamsulosin -- Sildosin -- Naftopidil -- α-Adrenergic antagonists and sexual dysfunction -- α1-blockers and intraoperative floppy iris syndrome -- Combination therapy -- Adverse effects of combination therapy for benign prostatic hyperplasia -- Summary -- Chapter 8 5α-Reductase Inhibitors -- Introduction and history of 5α-reductase inhibitors. Hypothetical rationale, preclinical, and early clinical (phase I-II) evidence for the use of 5α-reductase inhibitors in benign prostatic hyperplasia -- Clinical evidence (phase III or higher) for the use of 5α-reductase inhibitors in benign prostatic hyperplasia -- Finasteride -- Dutasteride -- Finasteride versus dutasteride -- Side effects of 5α-reductase inhibitor treatment -- 5α-Reductase inhibitors and prostate cancer -- Bibliography -- Chapter 9 Antimuscarinics -- Introduction -- Mechanism of action -- Clinical studies -- Evidence in men with storage lower urinary tract symptoms -- Evidence in men with confirmed bladder outlet obstruction -- Comparison between agents -- Antimuscarinic safety in men with lower urinary tract symptoms/benign prostatic hyperplasia -- Other important treatment issues -- Practical aspects of antimuscarinic use -- Conclusion -- Conflict of interest -- Chapter 10 The Use of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia -- Introduction -- Epidemiology -- Lower urinary tract symptoms treatment -- Pathophysiology of lower urinary tract symptoms and the phosphodiesterase-5 signal pathway -- Nitric oxide synthase/cyclic guanosine monophosphate pathway -- Ras homolog gene family, member A/Ras homolog-kinase signaling -- Pelvic atherosclerosis and chronic hypoxia -- Autonomic hyperactivity -- Mechanism of action of phosphodiesterase-5 inhibitors in benign prostatic hyperplasia/lower urinary tract symptoms -- Bladder -- Prostate -- Vasculature -- Spinal cord -- Summary of randomized controlled trials of phosphodiesterase-5 inhibitors versus placebo -- Summary of randomized controlled trials of phosphodiesterase-5 inhibitors and urodynamics -- Safety. Evidence-based outcomes of alpha blocker/phosphodiesterase-5 inhibitor combination on lower urinary tract symptoms -- Indications and contraindications -- Limitations -- Chapter 11 Combination Medical Therapy for Male Lower Urinary Tract Symptoms -- Combination medical therapy: alpha receptor blocker + 5α-reductase inhibitor -- Introduction and mechanisms of action -- Small studies of short duration -- Placebo-controlled and direct comparator studies -- Adverse events of α1-blocker/5α-reductase inhibitor combination therapy (Table 11.3) -- Alpha adrenergic receptor blocker + antimuscarinics -- Subjective outcomes of α1-blocker/antimuscarinic combination therapy -- Objective outcomes of α1-blocker/antimuscarinic combination therapy -- Adverse events of α1-blocker/antimuscarinic combination therapy -- Alpha adrenergic receptor blocker + phosphodiesterase type 5 inhibitor -- Clinical studies -- Meta-analysis -- Bibliography -- Chapter 12 Complementary Therapy -- Phytotherapy -- Common compounds in phytochemicals -- β-Sitosterol -- Isoflavones -- Selected phytotherapeutic agents -- Saw palmetto (Serona repens) -- Pygeum (Pygeum africanum) -- Stinging nettle (Urtica dioica et urens) -- South African star grass (Hypoxis rooperi) -- Rye pollen (Secale cerale) -- Pumpkin seeds (Curcubita pepo L.) -- Flaxseed lignans -- Nutrients -- Zinc -- Amino acids -- Fatty acids -- Exercise -- Chapter 13 Open Simple Prostatectomy -- Introduction -- Open simple prostatectomy -- Surgical techniques -- Suprapubic transvesical prostatectomy (Freyer) -- Retropubic transcapsular prostatectomy (Millin) -- Simple perineal prostatectomy -- Perioperative antibiotic prophylaxis -- Postoperative management -- Functional outcomes -- Morbidity and mortality -- Minimally invasive alternatives of simple prostatectomy -- Laparoscopic simple prostatectomy. Robot-assisted simple prostatectomy -- Single-port transvesical enucleation of the prostate -- Bibliography -- Chapter 14 Minimally Invasive Therapies -- Overview -- Transurethral needle ablation of the prostate -- Transurethral microwave thermotherapy -- Transurethral ethanol ablation of the prostate -- Botulinum toxin A -- Bibliography -- Chapter 15 Holmium Laser Prostatectomy -- Introduction -- Laser physics -- History -- Holmium laser enucleation of the prostate technique -- Equipment -- Procedure -- Bladder neck incision -- Median lobe enucleation -- Lateral lobe enucleation -- Haemostasis -- Morcellation -- Modifications -- Patient selection -- Outcomes -- Learning curve -- Conclusion -- Bibliography -- Chapter 16 Benign Prostatic Hyperplasia: GreenLight Laser Therapy -- 532 nm wavelength laser -- 60 W data -- 80 W data -- 120 W -- 180 W 532 nm laser -- Complications -- Conclusion -- Bibliography -- Chapter 17 Principles of Electrocautery-Based Techniques -- Overview -- Monopolar transurethral resection of the prostate -- Early experience with monopolar electrovaporization technology -- Bipolar transurethral resection of the prostate -- Bibliography -- Index.
9781118437971
Lower Urinary Tract Symptoms.
Electronic books.
RC877 -- .M35 2014eb
616.6/5